A Retrospective Study to Identify Demographic and Clinical Risk Factors for the Development of
Cassandra Grello1, Monica Demecillo2, Kristyn Pierce2
1Department of Pediatrics, New York Presbyterian-Weill Cornell, New York City, New York, USA.
Abstract:
Methotrexate (MTX) has improved survival for children with acute lymphoblastic leukemia, but is associated with a 3%-7% incidence of neurotoxicity. This retrospective study showed a higher incidence of MTX neurotoxicity (11.3%) with the classic presentations of stroke-like syndrome (17/19), seizures (2/19), and the majority (14/19) showing characteristic radiographic findings. Most cases occurred during the consolidation phase, a median of 6 days after MTX exposure. Older age, Hispanic ethnicity, greater body mass index, and National Cancer Institute high-risk status were predictors of neurotoxicity, with only ethnicity remaining significant in adjusted analyses. Prophylactic leucovorin after repeated intrathecal MTX doses may be protective.
More Related Videos
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Factors Affecting Drug Response: Overview
Pharmacokinetics in Pediatric Patients: Drug Distribution


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)